AstraZeneca Announces Maryland Manufacturing Investment

TL;DR

AstraZeneca investing in Maryland manufacturing, filing 6-K.

AI Summary

AstraZeneca PLC announced a manufacturing investment in Maryland, USA, on November 24, 2025. The company, headquartered in Cambridge, UK, is filing a Form 6-K report with the SEC. This filing is related to their operations and does not specify a dollar amount for the investment.

Why It Matters

This investment signals AstraZeneca's commitment to expanding its manufacturing capabilities in the US, potentially impacting supply chains and local economies.

Risk Assessment

Risk Level: low — The filing is a routine report of foreign issuer and does not contain significant financial or operational news that would immediately impact risk.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report
• 001-11960 (company) — SEC File Number
• 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom (company) — Registrant's business address
• 20251124 (date) — Filing date

FAQ

From the Filing

0001654954-25-013401.txt : 20251124 0001654954-25-013401.hdr.sgml : 20251124 20251124065412 ACCESSION NUMBER: 0001654954-25-013401 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251124 FILED AS OF DATE: 20251124 DATE AS OF CHANGE: 20251124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251509546 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a6308i.htm ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND a6308i FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of November 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________     AstraZeneca PLC   INDEX TO EXHIBITS     1. AstraZeneca manufacturing investment in Maryland       24 November 2025       AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth     New capacity at AstraZeneca's Frederick and Gaithersburg facilities will accelerate production of cancer, rare and chronic disease medicines     Fourth major US manufacturing investment announced this year, advancing AstraZeneca's historic $50 billion commitment to medicines manufacturing and R&D     AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state including the retention of local roles, construction activity, and the creation of 300 highly skilled jobs.    The Frederick facility currently produces biologics, a type of medication used across AstraZeneca's portfolio of cancer, auto immune, respiratory and rare disease treatments. The planned expansion will nearly double commercial manufacturing capacity, enabling increased supply of existing medicines and, for the first time, production across the Company's rare disease